Benzinga | Aug 6, 2021 12:17PM EDT

Raymond James Maintains Outperform on NGM Biopharmaceuticals, Raises Price Target to $27

Raymond James analyst Steven Seedhouse maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Outperform and raises the price target from $22 to $27.